IL281802A - שימוש במעכב של מוביל משפחת ent בטיפול בסרטן ושילובו עם אנטגוניסט לקולטן אדנוסין - Google Patents

שימוש במעכב של מוביל משפחת ent בטיפול בסרטן ושילובו עם אנטגוניסט לקולטן אדנוסין

Info

Publication number
IL281802A
IL281802A IL281802A IL28180221A IL281802A IL 281802 A IL281802 A IL 281802A IL 281802 A IL281802 A IL 281802A IL 28180221 A IL28180221 A IL 28180221A IL 281802 A IL281802 A IL 281802A
Authority
IL
Israel
Prior art keywords
cancer
inhibitor
treatment
combination
receptor antagonist
Prior art date
Application number
IL281802A
Other languages
English (en)
Original Assignee
iTeos Belgium SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE20180115A external-priority patent/BE1026612B1/fr
Application filed by iTeos Belgium SA filed Critical iTeos Belgium SA
Publication of IL281802A publication Critical patent/IL281802A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
IL281802A 2018-09-27 2021-03-25 שימוש במעכב של מוביל משפחת ent בטיפול בסרטן ושילובו עם אנטגוניסט לקולטן אדנוסין IL281802A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737717P 2018-09-27 2018-09-27
BE20180115A BE1026612B1 (fr) 2018-09-27 2018-09-27 Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine
PCT/EP2019/076244 WO2020065036A1 (en) 2018-09-27 2019-09-27 Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist

Publications (1)

Publication Number Publication Date
IL281802A true IL281802A (he) 2021-05-31

Family

ID=68109305

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281802A IL281802A (he) 2018-09-27 2021-03-25 שימוש במעכב של מוביל משפחת ent בטיפול בסרטן ושילובו עם אנטגוניסט לקולטן אדנוסין

Country Status (4)

Country Link
JP (1) JP2022503879A (he)
BR (1) BR112021006033A2 (he)
IL (1) IL281802A (he)
WO (1) WO2020065036A1 (he)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3601296T1 (sl) 2017-03-30 2022-10-28 iTeos Belgium SA 2-okso-tiazolni derivati kot zaviralci A2A in spojine za uporabo pri zdravljenju raka
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
AU2020395495B2 (en) * 2019-12-02 2024-05-09 Astrazeneca Ab Solid pharmaceutical formulations of 6-(2-chloro-6-methylpyridin-4-yl)-5-(-4-fluorophenyl)-1,2,4-triazin-3-amine
WO2022178135A1 (en) 2021-02-17 2022-08-25 Iteos Belguim Sa Compounds, compositions and methods of treatment thereof
WO2023056910A1 (en) * 2021-10-06 2023-04-13 iTeos Belgium SA Processes for preparing a macrocyclic compound having ent1 inhibiting activity
WO2023059739A1 (en) * 2021-10-06 2023-04-13 iTeos Belgium SA Macrocyclic compounds having ent1 inhibiting activity

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140181A2 (en) * 2006-05-26 2007-12-06 King Pharmaceuticals Research And Development, Inc. Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
CN102869631B (zh) 2010-02-08 2016-09-07 埃西勒国际通用光学公司 包含具有防雾性能的抗反射涂层的光学制品
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US20130267515A1 (en) * 2010-10-26 2013-10-10 Alberta Health Services Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer
KR102611446B1 (ko) 2017-01-20 2023-12-06 아르커스 바이오사이언시즈 인코포레이티드 암-관련 장애의 치료를 위한 아졸로피리미딘
WO2018178338A1 (en) 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers

Also Published As

Publication number Publication date
WO2020065036A1 (en) 2020-04-02
BR112021006033A2 (pt) 2021-09-08
JP2022503879A (ja) 2022-01-12

Similar Documents

Publication Publication Date Title
IL281802A (he) שימוש במעכב של מוביל משפחת ent בטיפול בסרטן ושילובו עם אנטגוניסט לקולטן אדנוסין
ZA202100195B (en) Purinone compounds and their use in treating cancer
ZA202002172B (en) Pde9 inhibitor and use thereof
DK3502667T3 (da) Lysdetekteringsanordninger med beskyttende foring og metoder i forbindelse med samme
SG11202008696RA (en) Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers
IL279347A (he) אנטגוניסט לגרמלין-1 למניעה וטיפול בסרטן
IL274836A (he) תכנית מינון של וידופלודימוס לשימוש במניעת או טיפול במחלות דלקתיות כרוניות ו/או מחלות אוטואימוניות
LT3601296T (lt) 2-okso-tiazolo derivatai kaip a2a inhibitoriai ir junginiai, skirti naudoti gydant vėžį
IL282350A (he) מעכבים ברנני-rgmc ושימוש בהם
IL281999A (he) מעכבי אינטראקציה yap/taz-tead והשימוש שלהם בטיפול בסרטן
IL276814A (he) אינדזול-3-קרבוקסאמידים מותמרים ב 5-הטרואריל והכנה ושימוש בהם
SG11202102338TA (en) Quinuclidine-3-one derivatives and their use in cancer treatment
IL284053A (he) תרכובות חדשות והשימוש בהן בטיפול
EP3899292C0 (en) SCREW WITH MILLING RIBS FOR MILLING THE SCREW AND USING THE SCREW
IL282527A (he) תולדות 5-אזאינדאזול והשימוש בהן
HUE058652T2 (hu) Vegyületek és felhasználásuk a schisotosomiasis kezelésében
IL277749A (he) תרכובות פלאדיאנוליד והשימוש שלהם
IT201700030541A1 (it) Composizione e kit per uso nella prevenzione dell’onicomicosi recidivante
SG11202108832XA (en) Anti-ang2 antibody and use thereof
PT3617533T (pt) Parafuso e sua utilização
MX2021003500A (es) Uso de un inhibidor de un transportador de la familia ent en el tratamiento del cáncer y su combinación con un antagonista del receptor de adenosina.
IL277112A (he) תרכובות לעיכוב הגרעה של חלבונים ושיטות לשימושן בטיפול בסרטן
EP3793585A4 (en) NEADJUVANT CANCER TREATMENT COMPRISING THE COMBINATION OF AN IMMUNOTOXIN AND A CHECKPOINT INHIBITOR
HK1254107A1 (zh) 抗trailr2抗體-毒素-偶聯物及其在抗腫瘤治療中的藥物用途
SG11202103488XA (en) Galactose rapid quantitative detection system and use thereof